Dennis Rademaker, DO
Allergy & Immunology · Munster, INNPI 1457328411
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 336 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,411 and has fallen 51.3% since, to $687 in 2025. That places this record below the midpoint for allergy & immunology clinicians in IN, where the typical reported total is $4,393.
Across 336 payments — averaging $13.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$684
- GSK$636
- Alk-abello, Inc$587
- Optinose US, Inc.$537
- Novartis$306
- CSL Behring$257
- plus $1K from 21 others
What the payments were for
- Food & beverage$4,33699%
- Education$571%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 38 | $684 |
| GSK | 65 | $636 |
| Alk-abello, Inc | 52 | $587 |
| Optinose US, Inc. | 51 | $537 |
| Novartis | 23 | $306 |
| CSL Behring | 16 | $257 |
| Covis Pharma GmbH | 13 | $195 |
| Amgen | 14 | $191 |
| Teva Pharmaceuticals USA, Inc. | 11 | $178 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $132 |
| Shire North American Group Inc | 8 | $113 |
| Sanofi | 6 | $89 |
| Regeneron Healthcare Solutions, Inc. | 5 | $73 |
| Kaleo, Inc. | 5 | $73 |
| Grifols USA, LLC | 4 | $63 |
| Boehringer Ingelheim | 4 | $60 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $45 |
| Biocryst US Sales Co., LLC | 1 | $24 |
| Hospira, Inc. | 1 | $23 |
| Alcon | 1 | $18 |
| Genentech USA, Inc. | 1 | $18 |
| Kedrion Biopharma, Inc. | 1 | $18 |
| Philips North America LLC | 1 | $16 |
| Merck | 1 | $15 |
| Mallinckrodt Enterprises LLC | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Phadia US Inc. | 1 | $13 |
How this compares
$4,393 in reported general payments places this provider in the 50th percentile of 49 allergy & immunology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 26 | $72,018 |
| Spiriva RespimatTiotropium Bromide | 60 | $53,282 |
| Dupixent SyringeDupilumab | 13 | $49,886 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $21,006 |
| Zileuton ErZileuton | 14 | $20,152 |
| SymbicortBudesonide/Formoterol Fumarate | 41 | $17,052 |
| Breo ElliptaFluticasone/Vilanterol | 33 | $16,589 |
| DuleraMometasone/Formoterol | 24 | $11,331 |
| Arnuity ElliptaFluticasone Furoate | 21 | $11,159 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 35 | $9,504 |
| XhanceFluticasone Propionate | 13 | $8,120 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 36 | $4,988 |
| Azelastine Hcl | 109 | $4,256 |
| Epinephrine | 21 | $2,862 |
| Olopatadine Hcl | 20 | $2,694 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSpiriva Respimat | $60 | $53,28260 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $636 | $48,75378 claims |
| AstraZenecaSymbicort | $684 | $17,05241 claims |
| MerckDulera | $15 | $11,33124 claims |
| Optinose US, Inc.Xhance | $537 | $8,12013 claims |
| Hikma Pharmaceuticals USAEpinephrine | $14 | $2,86221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 49 allergy & immunology providers in Indiana.
Other allergy & immunology in Munster
- Meaghan MisiaszMunster$3K
- Nabeel FarooquiFishers$1.2M
- David PattersonNoblesville$252K
- William SmitsFort Wayne$203K
- Steven WiseIndianapolis$137K
- Majed KoleilatEvansville$122K
- Pinkus GoldbergIndianapolis$89K
- Douglas NeeldFort Wayne$77K
- Pooja PatelMerrillville$55K
- Mitchell SmithGreenwood$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.